335 related articles for article (PubMed ID: 25263320)
21. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.
Steensma DP; Baer MR; Slack JL; Buckstein R; Godley LA; Garcia-Manero G; Albitar M; Larsen JS; Arora S; Cullen MT; Kantarjian H
J Clin Oncol; 2009 Aug; 27(23):3842-8. PubMed ID: 19528372
[TBL] [Abstract][Full Text] [Related]
22. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.
Batty GN; Kantarjian H; Issa JP; Jabbour E; Santos FP; McCue D; Garcia-Manero G; Pierce S; O'Brien S; Cortés JE; Ravandi F
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):205-10. PubMed ID: 20511166
[TBL] [Abstract][Full Text] [Related]
23. Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress.
Venugopal S; Shallis RM; Zeidan AM
Expert Rev Anticancer Ther; 2023; 23(9):903-911. PubMed ID: 37470508
[TBL] [Abstract][Full Text] [Related]
24. A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome.
Almasri J; Alkhateeb HB; Firwana B; Sonbol MB; Damlaj M; Wang Z; Murad MH; Al-Kali A
Syst Rev; 2018 Sep; 7(1):144. PubMed ID: 30227896
[TBL] [Abstract][Full Text] [Related]
25. Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly "promising"?
Brunner AM; Fell G; Steensma DP
Blood Adv; 2022 May; 6(9):2854-2866. PubMed ID: 35143613
[TBL] [Abstract][Full Text] [Related]
26. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Garcia JS; Flamand Y; Penter L; Keng M; Tomlinson BK; Mendez LM; Koller P; Cullen N; Arihara Y; Pfaff K; Wolff JO; Brunner AM; Galinsky I; Bashey A; Antin JH; Cutler C; Ho V; Jonas BA; Luskin MR; Wadleigh M; Winer ES; Savell A; Leonard R; Robertson T; Davids MS; Streicher H; Rodig SJ; Ritz J; Wu CJ; DeAngelo DJ; Neuberg D; Stone RM; Soiffer RJ
Blood; 2023 Apr; 141(15):1884-1888. PubMed ID: 36332187
[TBL] [Abstract][Full Text] [Related]
27. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
Usuki K; Ohtake S; Honda S; Matsuda M; Wakita A; Nawa Y; Takase K; Maeda A; Sezaki N; Yokoyama H; Takada S; Hirano D; Tomikawa T; Sumi M; Yano S; Handa H; Ota S; Fujita H; Fujimaki K; Mugitani A; Kojima K; Kajiguchi T; Fujimoto K; Asou N; Usui N; Ishikawa Y; Katsumi A; Matsumura I; Miyazaki Y; Kiyoi H
Int J Hematol; 2024 Feb; 119(2):130-145. PubMed ID: 38091231
[TBL] [Abstract][Full Text] [Related]
28. Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine.
Li H; Wang Y; Pang X; Xie C; Deeg JH; Wang H; Wan T; Wu J; Guan F; Li X
Haematologica; 2020 Oct; 105(10):e502. PubMed ID: 33054092
[No Abstract] [Full Text] [Related]
29. [Platelet Count Doubling after One Course of Demethylated Drug Therapeutic Predicts the Treatment Response and Efficacy of Patients with Myelodysplastic Syndrome].
Hui H; Yu HY; Li DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):184-189. PubMed ID: 38387919
[TBL] [Abstract][Full Text] [Related]
30. Eprenetapopt (APR-246) and Azacitidine in
Sallman DA; DeZern AE; Garcia-Manero G; Steensma DP; Roboz GJ; Sekeres MA; Cluzeau T; Sweet KL; McLemore A; McGraw KL; Puskas J; Zhang L; Yao J; Mo Q; Nardelli L; Al Ali NH; Padron E; Korbel G; Attar EC; Kantarjian HM; Lancet JE; Fenaux P; List AF; Komrokji RS
J Clin Oncol; 2021 May; 39(14):1584-1594. PubMed ID: 33449813
[TBL] [Abstract][Full Text] [Related]
31. Frontline treatment options for higher-risk MDS: can we move past azacitidine?
Sallman DA; Xie Z
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):65-72. PubMed ID: 38066872
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?
Bouchla A; Papageorgiou SG; Symeonidis A; Sakellari I; Zikos P; Thomopoulos TP; Hatzimichael E; Galanopoulos A; Vyniou NA; Kotsianidis I; Pappa V
Leukemia; 2023 Dec; 37(12):2517-2519. PubMed ID: 37816955
[No Abstract] [Full Text] [Related]
33. Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors.
Ye C; Jiang N; Zheng J; Zhang S; Zhang J; Zhou J
Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189066. PubMed ID: 38163523
[TBL] [Abstract][Full Text] [Related]
34. Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabine.
Steensma DP; Porcher JC; Litzow MR; Hogan WJ; Arora S; Van Laar ES
Leuk Res; 2009 Jul; 33(7):e81-2. PubMed ID: 19157545
[No Abstract] [Full Text] [Related]
35. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS.
Sasaki K; Jabbour E; Montalban-Bravo G; Darbaniyan F; Do KA; Class C; Short NJ; Kanagal-Shamana R; Kadia T; Borthakur G; Pemmaraju N; Cortes J; Ravandi F; Alvarado Y; Chien K; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Soltysiak K; Yang H; Kantarjian HM; Garcia-Manero G
NEJM Evid; 2022 Oct; 1(10):EVIDoa2200034. PubMed ID: 38319837
[TBL] [Abstract][Full Text] [Related]
36. All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex.
Wang L; Zhang Q; Ye L; Ye X; Yang W; Zhang H; Zhou X; Ren Y; Ma L; Zhang X; Mei C; Xu G; Li K; Luo Y; Jiang L; Lin P; Zhu S; Lang W; Wang Y; Shen C; Han Y; Liu X; Yang H; Lu C; Sun J; Jin J; Tong H
Br J Cancer; 2023 Feb; 128(4):691-701. PubMed ID: 36482192
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of epigenetic agents for older patients with acute myeloid leukemia and myelodysplastic syndrome in randomized controlled trials: a systematic review and network meta-analysis.
Oh S; Kim E
Clin Exp Med; 2023 Oct; 23(6):2705-2714. PubMed ID: 36964818
[TBL] [Abstract][Full Text] [Related]
38. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies.
Jabbour E; Issa JP; Garcia-Manero G; Kantarjian H
Cancer; 2008 Jun; 112(11):2341-51. PubMed ID: 18398832
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression.
Kazachenka A; Young GR; Attig J; Kordella C; Lamprianidou E; Zoulia E; Vrachiolias G; Papoutselis M; Bernard E; Papaemmanuil E; Kotsianidis I; Kassiotis G
Genome Med; 2019 Dec; 11(1):86. PubMed ID: 31870430
[TBL] [Abstract][Full Text] [Related]
40. Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.
Emadi A; Faramand R; Carter-Cooper B; Tolu S; Ford LA; Lapidus RG; Wetzler M; Wang ES; Etemadi A; Griffiths EA
Am J Hematol; 2015 May; 90(5):E77-9. PubMed ID: 25651001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
